News & Updates

In patients who are hospitalized for COVID-19, treatment with empagliflozin does not appear to have any positive impact on outcomes such as 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death, as shown in the open-label RECOVERY trial.

Gut-brain interaction disorders and persistent gastrointestinal (GI) symptoms prevail 12–18 months following COVID-19 hospitalization, and these prolonged GI issues are associated with the severity of the symptoms during hospitalization and the psychological toll of the illness experience, according to a study.

During the COVID-19 lockdown period, major trauma cases such as road traffic accidents and worksite injuries have decreased while the opposite is true for interpersonal violence, which has shown a relative increase, according to a Singapore study.

Among individuals with cirrhosis and cured hepatitis C virus (HCV) infection, the risk of hepatocellular carcinoma tapers off progressively through 6 years after HCV eradication, as shown in a study. However, the risk remains above thresholds that require screening.

In the CONFIDENT trial, convalescent plasma (CCP) conferred a mortality benefit for patients with COVID-19-induced acute respiratory distress syndrome (ARDS) who were on invasive mechanical ventilation (IMV).